Three studies related to HLB's investigational anticancer drug candidates rivoceranib and rafaftinib have been accepted for presentation at the annual congress of the European Society for Medical Oncology (ESMO). While the Phase 2 trial of rivoceranib in patients with metastatic thymic epithelial tumors was selected for a rapid oral presentation—confirming academic interest—the U.S. approval prospects for the liver cancer treatment are expected to be more directly influenced by quality control issues at Chinese partner Hengrui Pharma's manufacturing facilities and the resubmission process than by the conference presentation.

■ 3 ESMO Presentations Accepted... Thymic Epithelial Tumor Phase 2 Selected for 'Rapid Oral Presentation'

According to reports by Biospectator and The Bio, Elevate Therapeutics, HLB's U.S. subsidiary, will present three studies related to rivoceranib and rafaftinib at ESMO. The presentation topics include one study on rivoceranib monotherapy, one sub-analysis of the rivoceranib and camrelizumab combination therapy, and one post-hoc analysis of a rafaftinib clinical trial.

The most closely watched study is an investigator-initiated Phase 2 trial of rivoceranib in patients with metastatic thymic epithelial tumors whose disease progressed after prior platinum-based chemotherapy. It was accepted for a rapid oral presentation session rather than a general poster, indicating that the congress evaluated the study's importance and interest level relatively highly.

However, the selection of the presentation format itself does not guarantee drug approval or clinical success. The actual efficacy and safety of the study can only be evaluated once specific clinical figures—such as objective response rate, progression-free survival, overall survival, and serious adverse events—are disclosed.

The second presentation is a sub-analysis of the global Phase 3 CAREES-310 trial evaluating the rivoceranib and camrelizumab combination therapy in patients with unresectable hepatocellular carcinoma. The analysis examines the impact of early antibiotic use on treatment efficacy. CAREES-310 serves as the clinical basis for the liver cancer combination therapy for which HLB is pursuing U.S. approval. However, the sub-analysis is not a new trial proving the primary efficacy results of the entire Phase 3 study; rather, it is primarily an additional analysis of the impact of specific patient conditions or treatment environments.

The third presentation is a post-hoc analysis of the ReFocus Phase 1/2 trial of rafaftinib, an FGFR2-targeted therapy. It evaluates the impact of prior immuno-oncology treatment on the risk of mucocutaneous adverse reactions and will be presented as an e-poster. Since rafaftinib is a separate candidate from rivoceranib, this presentation should not be interpreted as directly linked to the U.S. approval chances of the rivoceranib and camrelizumab combination therapy.

■ FDA Approval Variable: API Facility Issues Partially Resolved, Finished Drug Facility Remediation 'Ongoing'

HLB's core regulatory variable is the U.S. approval of its liver cancer combination therapy. Elevate Therapeutics has been pursuing approval for the rivoceranib and camrelizumab combination as a first-line treatment for unresectable or metastatic hepatocellular carcinoma. Rivoceranib is an oral targeted anticancer drug that inhibits VEGFR-2, which is involved in tumor angiogenesis.

According to Yonhap News Agency and Chosun Biz, the FDA recently issued another Complete Response Letter (CRL) for the combination therapy. According to the company, the core of the CRL involved points related to pharmaceutical manufacturing and quality control standards at Chinese partner Hengrui Pharma's manufacturing facilities. Notably, the focus was on manufacturing facility issues rather than clinical efficacy itself. Reuters also reported that the combination therapy from Elevate and Hengrui failed to secure FDA approval due to manufacturing facility deficiencies, marking the third time approval has been denied for this combination.

The manufacturing facility issue needs to be examined by dividing it into Active Pharmaceutical Ingredient (API) and finished drug facilities. HLB stated that the FDA inspection result for Hengrui Pharma's rivoceranib API manufacturing facility was classified as 'Voluntary Action Indicated' (VAI). According to Yonhap News, the FDA's inspection close-out letter included language stating that this classification would not affect the evaluation of pending approval applications associated with that facility. A VAI classification means the FDA identified violations but determined they do not require immediate regulatory enforcement action, which can be interpreted as a signal that some uncertainty surrounding the API facility has been reduced.

However, this should not be extrapolated to mean that all reasons for the CRL have been completely resolved. Smart Today reported that while the API facility inspection has concluded, the rivoceranib finished drug manufacturing facility, which underwent a separate inspection, is still undergoing remediation work to address FDA observations. Newsis also reported that the finished drug facility was cited for issues including a lack of cleaning validation evidence, inadequate oversight by the quality control unit, delays in foreign particle testing of stored samples, and missing stability analyses for certain products.

Therefore, even if the API facility issue is resolved, the approval process could be delayed again if corrective actions at the finished drug facility are not completed to the level demanded by the FDA.

■ Form 483 Secured to Formulate Response Strategy... Resubmission Timing and Review Classification are Key

A Form 483 is a document issued by FDA investigators to a manufacturer detailing observed problems during an inspection. The mere issuance of the form does not result in the final rejection of a product application, but regulatory risk can only be reduced if the manufacturer submits sufficient corrective and preventive action (CAPA) data that the FDA accepts.

According to Money Today, HLB stated that it has obtained the Form 483 issued during the inspection of Hengrui Pharma's manufacturing facilities and will formulate a response strategy by analyzing the specific observations, Hengrui Pharma's response documents, and CAPA plans. HLB plans to determine the resubmission method and timing through consultations with the FDA.

Once the resubmission is received, the review period will vary depending on the review classification. Typically, the FDA may apply a relatively short review period if the scope of the requested supplements is limited, but the timeline could be extended if the agency determines that a facility re-inspection or additional data review is necessary. Therefore, how the FDA classifies the application upon resubmission is just as important as when the resubmission is submitted.

■ ESMO Presentation ≠ FDA Approval... 5 Indicators for Investors to Verify

The ESMO presentation and the FDA approval process are fundamentally different in nature. An academic congress presentation is an event that showcases the potential clinical utility of a candidate drug and researcher interest, whereas FDA approval is a regulatory process that comprehensively evaluates not only clinical efficacy and safety but also the manufacturing process, quality control, and consistency of commercial production.

This ESMO presentation could serve as an opportunity to expand the academic value of rivoceranib. In particular, if the results of the Phase 2 trial in thymic epithelial tumors are positively received, it could highlight the potential for developing the drug for indications beyond liver cancer. However, the study is an investigator-initiated Phase 2 trial, and its patient population, method of administration, and development stage differ from the liver cancer combination therapy submitted for U.S. approval. The presentation results will not resolve the quality control issues at Hengrui Pharma's manufacturing facilities or directly expedite the approval of the liver cancer treatment. The indicators investors should monitor are as follows:

First, the actual clinical data disclosed at ESMO. Rather than the mere acceptance for a rapid oral presentation, specific results for objective response rate, disease control rate, progression-free survival, overall survival, and adverse events are what matter.

Second, corrective actions at the finished drug manufacturing facility. It must be verified what improvement data Hengrui Pharma submitted regarding the FDA's observations and whether the FDA deems them sufficient.

Third, the timing of the resubmission and the review classification. Even if HLB announces its resubmission plan, it is difficult to pin down the product approval timeline until the FDA's receipt and review period are confirmed.

Fourth, distinguishing between the API facility and the finished drug facility. The mere fact that the API manufacturing facility inspection was concluded with a Voluntary Action Indicated (VAI) status does not mean the separate issues at the finished drug facility have been resolved.

Fifth, the difference between a congress abstract and official approval data. An academic presentation is a process that reveals only a portion of the study results, but regulatory authorities make approval decisions based on the complete clinical dataset and manufacturing and quality data.

HLB will continue to generate academic interest in its pipeline following the acceptance of three ESMO presentations for its rivoceranib and rafaftinib studies. In particular, the selection of the Phase 2 trial for thymic epithelial tumors for a rapid oral presentation offers an opportunity to confirm the potential for expanding rivoceranib's indications.

However, the variable that will most directly impact HLB's corporate value and stock price remains the FDA approval of the liver cancer combination therapy. Based on the information confirmed to date, while some uncertainty regarding the API manufacturing facility has diminished, remediation of the finished drug facility and the resubmission process remain. Rather than bundling the ESMO presentation and FDA approval together as a single positive catalyst, they should be viewed as separate processes. The focus should be on the quality of the specific clinical data at the congress, while the completion of manufacturing facility remediation and the FDA's official judgment should be verified during the approval process.

[This article was written with the assistance of AI. This article is for reference purposes for making investment decisions and does not recommend the purchase or sale of specific stocks. Investors must verify company disclosures and exchange materials before investing.]